DRC & Research News

This page shares the latest news in T1D research and DRC’s community.

Get the most recent diabetes research news, delivered straight to your inbox

Kaya Keutler DRC Volunteer

Meet a DRC Volunteer: Kaya Keutler

Kaya was diagnosed with type 1 diabetes when she was 13. That was also the point she knew she wanted to become a scientist and work in the research field of diabetes. Fast forward 15 years, Kaya is working on getting her doctoral degree at the Oregon Health & Science University. However, Kaya has realized that she wants to spend less time doing science and more time communicating current scientific knowledge to relevant audiences and the public. Her work for the DRC brings her one step closer to that goal. 

I was diagnosed with type 1 diabetes when I was 13. One of my closest cousins had lived with diabetes for about 10 years back then, so it wasn’t an unknown disease to me. Still, it felt like a bad diagnosis when an indifferent doctor delivered it to me in front of his note-taking students at a university clinic. Today I recognize it as a life-changing moment and am grateful for it, as it has made me the person I am. It also has significantly impacted my career decisions. I knew I wanted to become a scientist and work on a cure for diabetes back then. Although actively working in the field of diabetes research today, I now know it’s not that simple. There is so much we still need to learn about the disease and its treatment, and that includes both basic science as well as coming up with smart solutions for the everyday life of diabetic patients. “Let’s see what the science says” is a phrase I often use both at work and while engaging in managing my diabetes. I’ve found that what I know as a scientist does influence my treatment decisions quite a bit. I’ve reached out to volunteer for the DRC as I want to give others the power to make science-based treatment decisions and to better understand their disease, the research around it, and their options.

Kaya is now helping this organization by translating complex scientific language from DRC-funded researchers so that the community can understand the project better.

Learn More +

OUR PROJECTS

See our approved research projects and campaigns.

Role of the integrated stress response in type 1 diabetes pathogenesis
In individuals with type 1 diabetes (T1D), the insulin-producing beta cells are spontaneously destroyed by their own immune system. The trigger that provokes the immune system to destroy the beta cells is unknown. However, accumulating evidence suggest that signals are perhaps first sent out by the stressed beta cells that eventually attracts the immune cells. Stressed cells adapt different stress mitigation systems as an adaptive response. However, when these adaptive responses go awry, it results in cell death. One of the stress response mechanisms, namely the integrated stress response (ISR) is activated under a variety of stressful stimuli to promote cell survival. However, when ISR is chronically activated, it can be damaging to the cells and can lead to cell death. The role of the ISR in the context of T1D is unknown. Therefore, in this DRC funded study, we propose to study the ISR in the beta cells to determine its role in propagating T1D.
Wearable Skin Fluorescence Imaging Patch for the Detection of Blood Glucose Level on an Engineered Skin Platform
zhang
A Potential Second Cure for T1D by Re-Educating the Patient’s Immune System
L Ferreira
Validating the Hypothesis to Cure T1D by Eliminating the Rejection of Cells From Another Person by Farming Beta Cells From a Patient’s Own Stem Cells
Han Zhu
Taming a Particularly Lethal Category of Cells May Reduce/Eliminate the Onset of T1D
JRDwyer 2022 Lab 1
Can the Inhibition of One Specific Body Gene Prevent Type 1 Diabetes?
Melanie
Is Cholesterol Exacerbating T1D by Reducing the Functionality and Regeneration Ability of Residual Beta Cells?
Regeneration Ability of Residual Beta Cells
A Call to Question… Is T1D Caused by Dysfunctionality of Two Pancreatic Cells (β and α)?
Xin Tong
Novel therapy initiative with potential path to preventing T1D by targeting TWO components of T1D development (autoimmune response and beta-cell survival)
flavia pecanha